Scholar Rock Earnings Call - SCHOLAR ROCK HOLDING CORP

Financial Performance:

• Q3 2026 total revenue was $0.6 million, attributed to initial inventory shipments of iSEMBLE to the specialty network.
• Total operating expenses for Q3 were $106.6 million, including $17.9 million in non-cash stock-based compensation; adjusted operating expenses excluding stock-based compensation were $88.7 million.
• The company ended Q3 with $413.6 million in cash, cash equivalents, and marketable securities.
• In November 2026, a definitive agreement was executed to sell a priority review voucher for $205 million, providing significant non-dilutive capital upon closing.
• The balance sheet includes access to an additional $150 million under an existing debt facility, totaling available liquidity to fund operations without equity offerings.
• Cost of inventory was expensed prior to FDA approval; the company maintains minimal inventory levels at the specialty network.

Guidance and Future Outlook:

• Management expects steady, consistent patient enrollment and revenue growth in 2027, with the majority of patients enrolled through October 2026 anticipated to begin infusions in 2027 due to a 60–90 day timeline from prescription to infusion.
• Revenue trajectory is projected to be steady rather than a "bolus," driven by the time required for insurance verification, prior authorizations, and formulary approvals.
• U.S. launch is considered successful with strong demand outpacing current access; management anticipates payer policies aligning with the label to be published over the next six months.
• Europe launch is targeted for Germany in the second half of 2027 following a CHMP opinion expected in H1 2027.
• Japan launch is anticipated near the end of 2027, following a priority review with a 9-month cycle and subsequent 60–90 day pricing/reimbursement period.
• Top-line Phase 1 data for the next-generation candidate SRK439 is expected by year-end 2026.

Business Segments and Product Lines:

• iSEMBLE (Epitigromab): FDA-approved in mid-September for SMA patients aged 2+ on SMN2-targeted therapy; designated as the world's first muscle-targeted therapy.
• Clinical Development: Phase 2 FORGE study commenced dosing for FSHD (Fascioscapulohumeral Muscular Dystrophy); Phase 2 OPAL study is enrolling infants and toddlers under age 2.
• Pipeline: Development of a high-concentration subcutaneous (sub-Q) formulation is underway to enable caregiver administration; a PK bridging strategy is being explored with regulators.
• SRK439: Next-generation high-potency, high-affinity myostatin inhibitor with Phase 1 healthy volunteer dosing ongoing.
• Commercial Operations: Over 95% of top 140 SMA treatment centers engaged within six weeks; 98% of patient enrollments processed through the Scholarock support program.

Market and Competitive Landscape:

• The U.S. addressable market comprises approximately 6,600 patients currently on SMN2-targeted therapies.
• The global addressable market is estimated at 35,000 patients across ~50 countries.
• Early demand reflects a diverse patient mix: treatment-naive patients outnumber EAP/clinical trial transitions; pediatric patients represent the largest group, but a substantial number of adults (including those 60+) are enrolling.
• Patient diversity includes varying disease trajectories (improving, plateaued, declining) and background therapies (Evrysdi, Spinraza, high-dose Spinraza, and Zolgensma).
• Payer engagement has secured published policies aligned with the label from major payers Anthem and Centene, covering 47 million lives.

Risks and Challenges:

• Access Delays: Initial reimbursement delays and denials are common for first-in-class therapies; current turnaround from prescription to infusion is 60–90 days due to unspecified J-codes, lack of payer policies, and hospital formulary delays.
• J-Code Timeline: The specific J-code application is filed with an expected availability of April 1, 2027, which currently contributes to administrative delays.
• Safety Labeling: The label includes a warning for bone fractures; management reports no negative impact on demand or prescribing patterns to date.
• Operational Complexity: Varied patient locations and insurance requirements necessitate individualized support for each patient to navigate the infusion site and payer landscape.

Management Commentary and Tone:

• Management tone is described as confident, disciplined, and urgent, characterizing the company as transitioning successfully to a commercial stage.
• David Hillel (CEO) emphasized the company is "operating from a position of great strength" with no immediate need for capital raises.
• Keith Woods (COO) highlighted the "extraordinary accomplishment" of reaching 95% of top centers in six weeks and expressed confidence that access is a matter of "when and not if."
• Management emphasized the "steady as she goes" nature of the launch, expecting sustained growth rather than a one-time spike.

Analyst Questions and Answers:

• Fracture Warning: Management confirmed no impact on demand or prescribing patterns despite the bone fracture warning in the label.
• Access Timelines: Q&A clarified that 60–90 day timelines will condense over time but will not disappear entirely due to the necessity of prior authorizations, similar to existing SMN2 therapies.
• Patient Mix: Analysts asked about the proportion of treatment-naive vs. EAP patients; management confirmed treatment-naive patients currently outnumber those transitioning from trials.
• Payer Policies: Specifics on Anthem and Centene confirm policies are aligned with the broad label without age or ambulatory status restrictions.
• Sub-Q Strategy: Discussion on the subcutaneous formulation indicated a PK bridging study is the primary path for regulatory approval, with potential to expand the market via home administration.
• Future Metrics: Management indicated they will continue reporting on treatment center penetration and payer coverage metrics alongside revenue.

Other Key Points:

• Global Expansion: The strategy includes building a 50-country operating platform, with Germany being the first target for European launch.
• Market Dynamics: Management views high-dose Spinraza usage as a "net positive" by expanding the motor neuron health segment, which complements iSEMBLE's muscle-targeted mechanism.
• Advocacy: Cure SMA sent a community-wide access letter to payers and governors to urge timely access to the therapy.
• Retainability: High retention rates from previous trials (93% of patients remaining on therapy after 7 years) suggest strong patient loyalty and continuation rates for iSEMBLE.